Frazier Life Sciences’ additional investment in Egetis Therapeutics

Recent work|October 28, 2024

Roschier advises US healthcare investor Frazier Life Sciences on its additional USD 10 million investment in Egetis Therapeutics. Roschier previously advised Frazier Life Sciences on its initial investment in Egetis during the fall of 2023.

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment. Egetis Therapeutics is listed on the Nasdaq Stockholm main market.

Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including venture funds focusing on company creation and private companies and a public long-only fund focused on small and mid-cap public companies.

Roschier’s advisory team comprised Pontus Enquist, Miikka Kujanpää, and Pontus Berganäs.